# Lipid regulation and metabolism in myelin repair

> **NIH NIH P20** · UNIVERSITY OF KANSAS LAWRENCE · 2020 · $139,009

## Abstract

All of the current therapies available for treating multiple sclerosis are anti-infllammatory agents that target 
the immune system, and there are no approved drugs that promote repair of demyelinated lesions, which is 
the underlying cause of neurological disability. Our long-term goal is to define how CNS lipids are regulated 
by changes in brain hormones and how this affects neurological disease. The overall objective in this 
application, which is the first step toward achieving our long-term goal, is to identify lipid-related genes that 
are important during remyelination and define how the lipidome changes during demyelination and 
remyelination. Our central hypothesis is that hormones promote myelination through transcriptional 
regulation of genes involved in lipid metabolism, and that regulation of lipids is critical for successful 
remyelination. Our hypotheses have been formulated based on studies showing that thyroid hormone 
regulates lipid-related genes in the brain and during oligodendrocyte progenitor cell (OPC) differentiation, 
which is an important step in myelination. In addition, several lipid classes including sterols and 
lysophosphatidic acids have been implicated in remyelination. The rationale that supports the proposed 
research is that it will identify lipid pathways for the development of new therapies for promoting myelin repair. 
The central hypothesis will be evaluated with the two following specific aims: (1) Identify lipid-related genes 
regulated by nuclear receptors and required for OPC differentiation; and (2) Map myelin lipid changes during 
remyelination. In the first aim, an OPC differentiation assay will be used to evaluate a panel of nuclear 
receptor ligands that have been implicated in myelination. RNA-sequencing will then be performed to identify 
lipid-related genes involved in OPC differentiation and membrane process extension. For the second aim, 
brain lipids will be isolated from an inducible conditional knockout mouse model of demyelination based on 
the Plp-CreERT;Myrffl/fl strain. Mass spectrometry analysis will be performed to profile the brain lipidomic 
changes in demyelinating and remyelinating phases of the disease course. The proposed research is 
innovative, in the applicant’s opinion, because two orthogonal approaches are being used to synergistically 
identify new lipid pathways of importance in remyelination. Upon completion of this proposed research, it is 
expected that one or more lipid pathways involved in CNS remyelination will be identified. This contribution 
is expected to be significant, because it will increase knowledge about how lipids are regulated during 
remyelination and may reveal a novel target for therapeutic intervention in diseases affected by 
demyelination. These studies will also provide necessary preliminary data for a competitive R01 grant 
application in the future.

## Key facts

- **NIH application ID:** 10242613
- **Project number:** 5P20GM103638-09
- **Recipient organization:** UNIVERSITY OF KANSAS LAWRENCE
- **Principal Investigator:** Meredith D Hartley
- **Activity code:** P20 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $139,009
- **Award type:** 5
- **Project period:** 2012-07-15 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10242613

## Citation

> US National Institutes of Health, RePORTER application 10242613, Lipid regulation and metabolism in myelin repair (5P20GM103638-09). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10242613. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
